Industries > Pharma > Companion Diagnostics (CDx) Market Report 2021-2031

Companion Diagnostics (CDx) Market Report 2021-2031

Forecasts by Product & Services (Assay, Kit, Software & Service, Software & Services), by Technology (PCR, ISH, NGS, IHC, Others (Multiplex Assay and Cellular Imaging Technologies)), by Indication (Cardiovascular, Neurological Diseases, Cancer, Infectious Diseases, Others (inflammatory and inherited diseases)), by End-User (Pharmaceutical & Biopharmaceutical Companies, Reference Laboratories, CROs, Others (Physicians, Hospitals, Academic Medical Centers, Payers) AND Regional and Leading National Market Analysis PLUS Analysis of Leading CDx Companies AND COVID-19 Recovery Scenarios

PUBLISHED: 07 June 2021
PAGES: 444
PRODUCT CODE: PHA1135
SUBMARKET: Diagnostics

Clear
WOOCS 2.2.1
SKU: PHA1135 Categories: , Tag:

Want to Know What is holding you back in the Companion Diagnostics Business?
Visiongain, a renowned market intelligence firm has published strategic report on ‘Global Companion Diagnostics Market’. This report explores the current and emerging opportunities in the Companion Diagnostics market. Companion diagnostic aids in identifying patients who are most likely to benefit from a particular therapeutic product. Growing precedence of companion diagnostics over traditional practice of “one-size-fits-all” therapies and accelerating demand for targeted therapy are increasing the adoption of companion diagnostics. However, high cost of developing companion diagnostic test is expected to thwart the market growth.

Huge Demand for Companion Diagnostics for cancer applications
Significant adoption of companion diagnostics for cancer applications has been observed. Major companies and contract manufacturers such as Thermo Fisher Scientific and Roche provide companion diagnostic products for cancer in different countries. Thermo Fisher had launched Oncomine Dx Target Test for the detection of NSCLC. Additionally rising demand of personalized medicine and growing use of biomarkers for cancer diagnosis are expected to boost the demand.

Companion Diagnostics Market-our new study reveals current trends, technological advancements, and predicted revenues
Where the Companion Diagnostics market is heading? If you are involved in this industry you must read this newly updated report. Visiongain’s report shows you the potential revenue streams to 2031, assessing data, trends, opportunities and business prospects there.

Owing to the COVID-19 pandemic, the supply chain and demand of Companion Diagnostics has been affected in 2020. But it is not just COVID-19 that affects the future of Companion Diagnostics. This unique senior report tells you what direction the market will take – and it tells you today.

Discover how to stay ahead
Our 440+ page report provides 300+ tables, charts, and graphs.

Read on to discover the most lucrative areas in the industry and the future market prospects. Our study lets you assess forecasted sales at overall world market and regional level. See financial performance of companies, trends, opportunities, and revenue growth. Much opportunity remains in this growing Companion Diagnostics Market. See how to exploit the opportunities.

UNIQUE COVID-19 VARIATIONS– only available in this Visiongain report are dedicated analysis of 4 different rebound scenarios of how the market will develop – no matter how COVID-19 affects the economy.

To access the data contained in this document please email contactus@visiongain.com

Forecasts to 2030 and other analyses reveal the commercial prospects
• In addition to revenue forecasting to 2030, our new study provides you with recent results, growth rates, and market shares, key player positioning, and an exhaustive product portfolio comparison of key vendors
• You find original analyses, with business outlooks and developments which would be useful to tap potential business areas for key players
• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges, SWOT analysis), product profiles and commercial developments.

Which Factors are Fuelling Companion Diagnostics Industry Growth?
• Growing precedence of companion diagnostics over traditional practice of “one-size-fits-all” therapies
• Accelerating demand for targeted therapy
• Growing importance of personalized medicine to pave the way for companion diagnostic
• Increasing global burden of cancer
• Increase in scope of application of companion diagnostics

Which Factors are Restraining Growth?
• High cost of developing companion diagnostic test to impede market growth
• Challenges associated with uncertain reimbursement scenario in different regions

Forecasts to 2031 and other analyses reveal the commercial prospects
• In addition to revenue forecasting to 2031, our new study provides you with recent results, growth rates, and market shares.
• You find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), SWOT Analysis, Porter’s Analysis, product profiles and commercial developments.

CTA

Report Scope
Global Companion Diagnostics Market 2021-2031 is segmented on the basis of Product, Mode, End User and Geography.

Revenue and growth forecasts from 2021 to 2031 for the Global Companion Diagnostics Market by Products & Services:
• Assay, Kit, Software & Service
• Software & Services

Revenue and growth forecasts from 2021 to 2031 for the Global Companion Diagnostics Market by Technology:
• PCR
• ISH
• NGS
• IHC
• Others

Revenue and growth forecasts from 2021 to 2031 for the Global Companion Diagnostics Market by Indication:
• Cardiovascular
• Neurological Diseases
• Cancer
• Infectious Diseases
• Others

Revenue and growth forecasts from 2021 to 2031 for the Global Companion Diagnostics Market by End-User:
• Pharmaceutical & Biopharmaceutical Companies
• Reference Laboratories
• CROs
• Others

Revenue and growth forecasts from 2021 to 2031 for the Global Companion Diagnostics Market by Region:

• North America
• U.S.
• Canada

• Europe
• Germany
• France
• UK
• Italy
• Spain
• Switzerland
• Rest of Europe

• Asia-Pacific
• Japan
• China
• India
• Australia
• Rest of APAC

• LAMEA
• Brazil
• Mexico
• Rest of LAMEA

Companion Diagnostics (CDx) Market Report 2021-2031
Need industry data? Please contact us today.

• Our study discusses the selected leading companies that are the major players in the Companion Diagnostics industry:
• Roche
• Agilent Technologies
• Qiagen
• Thermo Fisher
• Abbott Laboratories
• Almac Group
• Danaher Corporation
• Illmina
• Biomurieux
• Myriad Genetics
• Sysmex Corporation
• Guardant Health
• Icon
• Abnova Corporation
• Biogenex Laboratories

How the Companion Diagnostics Market report helps you
In summary, our 440+ page report provides you with the following knowledge:
• What is the current size of the overall global Companion Diagnostics market? How much will this market be worth from 2021 to 2031?
• What are the main drivers and restraints that will shape the overall Companion Diagnostics market over the next ten years?
• What are the main segments within the overall Companion Diagnostics market? How much will each of these segments be worth for the period 2021 to 2031? How will the composition of the market change during that time, and why?
• What factors will affect that industry and market over the next ten years?
• Which are the leading companies and what are their activities, results, developments, and prospects?
• What are the main trends that will affect the world Companion Diagnostics market between 2021 and 2031?
• What are the main strengths, weaknesses, opportunities, and threats for the market?
• How will the global Companion Diagnostics market evolve over the forecasted period, 2021 to 2031?
• Revenue forecasts to 2030 for 4 regional and 10 key national markets – the report highlights market growth prospects for key countries such as the U.S., Canada, Germany, UK, France, Italy, Spain, Switzerland, China, Japan, Australia, and India. The report also highlights growth potential in Latin America as well as Middle East & Africa.
• Prospects for established firms and those seeking to enter the market– including company profiles for over 15 of the major companies involved in the Companion Diagnostics market

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.

Information found nowhere else
With our newly report title, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain’s study is for everybody needing commercial analyses for the Companion Diagnostics Market and leading companies. You will find data, trends and predictions.

Get our report today Companion Diagnostics Market Forecast 2021-2031: Forecast by Products and Services (assay & kit and software & services), by technology (PCR, ISH, NGS, IHC, and Others), by indications (cardiovascular, neurological diseases, cancer, infectious diseases, and others), by End User (pharmaceutical & biopharmaceutical companies, reference laboratories, CROs, and others), and By Region (North America, Europe, Asia Pacific, and LAMEA)

The Companion Diagnostics Market 2021-2031 report will be of value to anyone who wants to better understand the market and its various segments. It will be useful for businesses who wish to better comprehend the part of the market they are already involved in, or those wishing to enter or expand into a different regional or technical part of the digital healthcare industry.

To access the data contained in this document please email contactus@visiongain.com

Buy our report today Companion Diagnostics (CDx) Market Report 2021-2031: Forecasts by Product & Services (Assay, Kit, Software & Service, Software & Services), by Technology (PCR, ISH, NGS, IHC, Others (Multiplex Assay and Cellular Imaging Technologies)), by Indication (Cardiovascular, Neurological Diseases, Cancer, Infectious Diseases, Others (inflammatory and inherited diseases)), by End-User (Pharmaceutical & Biopharmaceutical Companies, Reference Laboratories, CROs, Others (Physicians, Hospitals, Academic Medical Centers, Payers) AND Regional and Leading National Market Analysis PLUS Analysis of Leading CDx Companies AND COVID-19 Recovery Scenarios. Avoid missing out by staying informed – order our report now.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Do you have any custom requirements we can help you with? Any need for a specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com

Download sample pages

Complete the form below to download your free sample pages for Companion Diagnostics (CDx) Market Report 2021-2031


Download sample pages

Complete the form below to download your free sample pages for Companion Diagnostics (CDx) Market Report 2021-2031


Latest Pharma news

Visiongain Publishes Pharmaceutical Spray Drying Market Report 2021-2031

The rising prevalence of oncological disorders, lung infections, rising demand for customised drugs coupled with new orphan diseases discoveries, are few of the major reasons responsible for development of pharmaceutical spray drying market.

25 October 2021

READ

Visiongain Publishes Clinical Trial Supplies Market Report 2021-2031

Deviating from protocols raises the danger of missing or delaying data collection from current investigations. This highlights the growing importance of digital medicine, which is being aided by advancements in cloud, mobile, and IoT technology.

11 October 2021

READ

Visiongain Publishes Drug Discovery Informatics Market Report 2021-2031

High performance HPC and supercomputing technology have evolved substantially in China in the last decades, leading to extraordinary accomplishments. HPC-based and combined pharmaceutical chemical and computational biology computational discovery and design has become a significant technique in drug research and development and is sponsored financially by the Chinese government.

07 October 2021

READ

Visiongain Publishes Pharma Wholesale and Distribution Market Report 2021-2031

Many health-care organizations are seeing organic growth at levels that their supply networks were never designed to handle. Others are frantically attempting to integrate diverse technology and procedures as part of a consolidation effort.

06 October 2021

READ

Categories